Trials / Completed
CompletedNCT03115255
Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab
Serum Concentrations of Vascular Endothelial Growth Factor in Infants Treated With Ranibizumab for Retinopathy of Prematurity
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- 4 Weeks – 3 Months
- Healthy volunteers
- Not accepted
Summary
To determine the serum concentrations of ranibizumab and vascular endothelial growth factor (VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal ranibizumab
Detailed description
Infants with ROP are studied. They received 0.25 mg or 0.5 mg of intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases) with vascularly active ROP. Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab. The serum concentrations of ranibizumab and VEGF are measured by enzyme-linked immunosorbent assay, and the changes of the serum VEGF levels are determined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intravitreal ranibizumab | 0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases) |
Timeline
- Start date
- 2017-05-01
- Primary completion
- 2018-05-31
- Completion
- 2018-06-30
- First posted
- 2017-04-14
- Last updated
- 2018-10-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03115255. Inclusion in this directory is not an endorsement.